<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680199</article-id><article-id pub-id-type="doi">10.3390/v16121860</article-id><article-id pub-id-type="publisher-id">viruses-16-01860</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Emerging SARS-CoV-2 Variants in Uganda in the Era of COVID-19 Vaccination</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1280-675X</contrib-id><name><surname>Bbosa</surname><given-names>Nicholas</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="af1-viruses-16-01860" ref-type="aff">1</xref><xref rid="af2-viruses-16-01860" ref-type="aff">2</xref><xref rid="af3-viruses-16-01860" ref-type="aff">3</xref><xref rid="c1-viruses-16-01860" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Kiiza</surname><given-names>Ronald</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af1-viruses-16-01860" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-6549-3550</contrib-id><name><surname>Ssekagiri</surname><given-names>Alfred</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af2-viruses-16-01860" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Namagembe</surname><given-names>Hamidah Suubi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af1-viruses-16-01860" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Nabirye</surname><given-names>Stella Esther</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af2-viruses-16-01860" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Kabuuka</surname><given-names>Danstan</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af2-viruses-16-01860" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0007-5630-2146</contrib-id><name><surname>Rwankindo</surname><given-names>Cleophous</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af2-viruses-16-01860" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4911-591X</contrib-id><name><surname>Kisakye</surname><given-names>Annet</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af4-viruses-16-01860" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Woldemariam</surname><given-names>Yonas T.</given-names></name><xref rid="af4-viruses-16-01860" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1390-109X</contrib-id><name><surname>Kusemererwa</surname><given-names>Sylvia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-viruses-16-01860" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0002-9885-2107</contrib-id><name><surname>Ongaria</surname><given-names>Terry A.</given-names></name><xref rid="af1-viruses-16-01860" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Kakande</surname><given-names>Ayoub</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-viruses-16-01860" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Abaasa</surname><given-names>Andrew</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-viruses-16-01860" ref-type="aff">1</xref><xref rid="af5-viruses-16-01860" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Kimbugwe</surname><given-names>Geofrey</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-viruses-16-01860" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6593-8727</contrib-id><name><surname>Bosa</surname><given-names>Henry Kyobe</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af6-viruses-16-01860" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Driwale</surname><given-names>Alfred</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af6-viruses-16-01860" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Mwenda</surname><given-names>Jason M.</given-names></name><xref rid="af7-viruses-16-01860" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name><surname>Worwui</surname><given-names>Archibald K.</given-names></name><xref rid="af7-viruses-16-01860" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0004-3789-8309</contrib-id><name><surname>Humphreys</surname><given-names>James</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af8-viruses-16-01860" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0001-1049-6973</contrib-id><name><surname>Cohuet</surname><given-names>Sandra</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af8-viruses-16-01860" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name><surname>Elliott</surname><given-names>Alison M.</given-names></name><xref rid="af1-viruses-16-01860" ref-type="aff">1</xref><xref rid="af9-viruses-16-01860" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name><surname>Ruzagira</surname><given-names>Eugene</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-viruses-16-01860" ref-type="aff">1</xref><xref rid="af5-viruses-16-01860" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Kaleebu</surname><given-names>Pontiano</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-viruses-16-01860" ref-type="aff">1</xref><xref rid="af2-viruses-16-01860" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9675-4234</contrib-id><name><surname>Ssemwanga</surname><given-names>Deogratius</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-viruses-16-01860" ref-type="aff">1</xref><xref rid="af2-viruses-16-01860" ref-type="aff">2</xref><xref rid="af3-viruses-16-01860" ref-type="aff">3</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Sun</surname><given-names>Caijun</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01860"><label>1</label>MRC/UVRI &#x00026; LSHTM Uganda Research Unit, Entebbe 256, Uganda; <email>ronald.kiiza@mrcuganda.org</email> (R.K.); <email>hamidah.namagembe@mrcuganda.org</email> (H.S.N.); <email>sylvia.kusemererwa@mrcuganda.org</email> (S.K.); <email>terry.ongaria@mrcuganda.org</email> (T.A.O.); <email>ayoub.kakande@mrcuganda.org</email> (A.K.); <email>andrew.abaasa@mrcuganda.org</email> (A.A.); <email>geofrey.kimbugwe@mrcuganda.org</email> (G.K.); <email>alison.elliott@lshtm.ac.uk</email> (A.M.E.); <email>eugene.ruzagira@mrcuganda.org</email> (E.R.); <email>pontiano.kaleebu@mrcuganda.org</email> (P.K.); <email>deogratius.ssemwanga@mrcuganda.org</email> (D.S.)</aff><aff id="af2-viruses-16-01860"><label>2</label>Uganda Virus Research Institute, Entebbe 256, Uganda; <email>assekagiri@gmail.com</email> (A.S.); <email>snabirye@uvri.go.ug</email> (S.E.N.); <email>danstankabuuka@gmail.com</email> (D.K.); <email>mwinekansiime93@gmail.com</email> (C.R.)</aff><aff id="af3-viruses-16-01860"><label>3</label>Department of Infection Biology, Faculty of Infectious and Tropical Diseases, London School of Hygiene &#x00026; Tropical Medicine, London WC1E 7HT, UK</aff><aff id="af4-viruses-16-01860"><label>4</label>World Health Organization (WHO) Country Office, Kampala 256, Uganda; <email>kisakyean@who.int</email> (A.K.); <email>TegegnYonas@outlook.com</email> (Y.T.W.)</aff><aff id="af5-viruses-16-01860"><label>5</label>Department of Infectious Diseases Epidemiology, London School of Hygiene &#x00026; Tropical Medicine, London WC1E 7HT, UK</aff><aff id="af6-viruses-16-01860"><label>6</label>Ministry of Health, Kampala 256, Uganda; <email>hskyobe@gmail.com</email> (H.K.B.); <email>driwalealfred2019@gmail.com</email> (A.D.)</aff><aff id="af7-viruses-16-01860"><label>7</label>The African Region Monitoring Vaccine Effectiveness (AFRO-MoVE) Network, World Health Organization&#x02014;Regional Office for Africa, Brazzaville 99324, Congo; <email>jmmathiu@yahoo.co.uk</email> (J.M.M.); <email>worwuia@who.int</email> (A.K.W.)</aff><aff id="af8-viruses-16-01860"><label>8</label>Epiconcept Company, 75011 Paris, France; <email>j.humphreys@epiconcept.fr</email> (J.H.); <email>s.cohuet@epiconcept.fr</email> (S.C.)</aff><aff id="af9-viruses-16-01860"><label>9</label>Clinical Research Department, London School of Hygiene &#x00026; Tropical Medicine, London WC1E 7HT, UK</aff><author-notes><corresp id="c1-viruses-16-01860"><label>*</label>Correspondence: <email>nicholas.bbosa@mrcuganda.org</email>; Tel.: +256-(0)-417-704000</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>16</volume><issue>12</issue><elocation-id>1860</elocation-id><history><date date-type="received"><day>23</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>24</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The emergence of SARS-CoV-2 variants has heightened concerns about vaccine efficacy, posing challenges in controlling the spread of COVID-19. As part of the COVID-19 Vaccine Effectiveness and Variants (COVVAR) study in Uganda, this study aimed to genotype and characterize SARS-CoV-2 variants in patients with COVID-19-like symptoms who tested positive on a real-time PCR. Amplicon deep sequencing was performed on 163 oropharyngeal/nasopharyngeal swabs collected from symptomatic patients. Genome assembly, lineage classification and phylogenetic analysis was performed using the Edge Bioinformatics pipeline version 2.4.0, Pangolin version 4.3.1 and iqtree version 2.3.6 software respectively. Of the 163 deep sequences analyzed between April 2023 and March 2024, the most common were XBB.1 lineages and sublineages (113, 69.3%), followed by JN.1* (12, 7.4%), XBB.2* (11, 6.7%) and FL* (11, 6.7%), EG* (7, 4.3%), others (BQ.1.1, FY.4.1, FY.4.1.2, GY.2.1, HK.27.1) (5, 3.1%) and CM* (4, 2.5%). XBB.1* dominated from April to July 2023; thereafter, other variants, including JN.1* were increasingly detected. There was no statistically significant association between vaccine status and lineage assignment (Fisher&#x02019;s exact test, <italic toggle="yes">p</italic>-value = 0.994). Our findings showed that the Omicron variant, specifically the XBB.1* lineage, was the dominant circulating virus. However, the emergence of the JN.1 variant that exhibits a significant spike protein mutation profile could impact COVID-19 transmission in Uganda.</p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>variants</kwd><kwd>omicron</kwd><kwd>vaccine</kwd><kwd>next-generation sequencing</kwd></kwd-group><funding-group><award-group><funding-source>World Health Organization (WHO)</funding-source></award-group><award-group><funding-source>Bill and Melinda Gates Foundation</funding-source></award-group><funding-statement>This research was funded by World Health Organization (WHO) and the Bill and Melinda Gates Foundation (WHO reference: 2022/1308549-0).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01860"><title>1. Introduction</title><p>The Medical Research Council (MRC)/Uganda Virus Research Institute (UVRI) &#x00026; London School of Hygiene and Tropical Medicine (LSHTM) Uganda Research Unit has contributed toward Uganda&#x02019;s SARS-CoV-2 response since the beginning of the coronavirus disease 2019 (COVID-19) pandemic [<xref rid="B1-viruses-16-01860" ref-type="bibr">1</xref>,<xref rid="B2-viruses-16-01860" ref-type="bibr">2</xref>,<xref rid="B3-viruses-16-01860" ref-type="bibr">3</xref>]. Uganda is in its fourth COVID-19 wave with a declining number of positive cases. During the first wave that occurred between December 2020 and January 2021, the A.23.1 variant dominated [<xref rid="B2-viruses-16-01860" ref-type="bibr">2</xref>]. The second wave occurred between May and July 2021, when the Delta variant was the dominant circulating virus. The third wave began around December 2021 and was largely driven by both Delta and Omicron at the beginning [<xref rid="B3-viruses-16-01860" ref-type="bibr">3</xref>] until Omicron replaced Delta to become the dominant variant to date. The SARS-CoV-2 Omicron variant (B.1.1.529) evolved with 10 genetic mutations within the viral receptor-binding domain and at least 32 genetic alterations in the spike protein and was classified as a Variant of Concern (VoC) in November 2021 by the World Health Organization (WHO) [<xref rid="B4-viruses-16-01860" ref-type="bibr">4</xref>]. The Omicron JN.1 (BA.2.86.1.1) lineage emerged around August 2023 after evolving from the BA.2.86 commonly known as &#x0201c;Pirola&#x0201d; and quickly became the most prevalent lineage in numerous countries that include the USA, China, Singapore, and India [<xref rid="B5-viruses-16-01860" ref-type="bibr">5</xref>]. JN.1 harbors a hallmark Leu455Ser spike protein mutation as well as three mutations in non-spike proteins, and compared to other lineages in the same group, it is more immune system evading and more easily transmissible [<xref rid="B6-viruses-16-01860" ref-type="bibr">6</xref>]. There is currently no evidence to prove that JN.1 causes more severe illness relative to other lineages but it has been reported to spread more easily and cause mild to moderate illness [<xref rid="B5-viruses-16-01860" ref-type="bibr">5</xref>]. </p><p>Multiple VoCs and variants of interest (VoIs) have been designated by the WHO based on their potential for expansion and replacement of prior variants and for causing new waves that are associated with increased circulation or illness [<xref rid="B7-viruses-16-01860" ref-type="bibr">7</xref>]. The advent of the alpha, beta, and delta SARS-CoV-2 variants was linked to new waves of infections globally. The virus continues to evolve as a result of genetic mutations or recombination in the viral genome during replication. The Omicron variant accounts for over 98% of the publicly available sequences since February 2022 and constitutes the genetic background from which new SARS-CoV-2 variants will likely emerge [<xref rid="B8-viruses-16-01860" ref-type="bibr">8</xref>].</p><p>Since the global rollout of COVID-19 vaccines, there has been remarkable progress in reducing the burden of the disease [<xref rid="B9-viruses-16-01860" ref-type="bibr">9</xref>,<xref rid="B10-viruses-16-01860" ref-type="bibr">10</xref>]. To date, six vaccines have been approved for use in Uganda that include, Jcovden (Johnson &#x00026; Johnson Innovative Medicine, Beerse, Belgium), Vaxzevria (Oxford University/AstraZeneca, Oxford/Cambridge, UK), Comirnaty (Pfizer/BioNTech, Mainz, Germany), Spikevax (Moderna, Cambridge, MA, USA), Sinopharm (Beijing Institute of Biological Products, Beijing, China) and CoronaVac (Sinovac Biotech, Beijing, China) [<xref rid="B11-viruses-16-01860" ref-type="bibr">11</xref>]. The national COVID-19 vaccine uptake and coverage reported between March 2021 and June 2022 was 63% for &#x02265;1 dose and 42% for &#x02265;2 doses, respectively [<xref rid="B12-viruses-16-01860" ref-type="bibr">12</xref>]. However, the emergence of SARS-CoV-2 variants that are capable of evading vaccine-induced immunity poses new challenges to public health efforts globally [<xref rid="B13-viruses-16-01860" ref-type="bibr">13</xref>,<xref rid="B14-viruses-16-01860" ref-type="bibr">14</xref>]. The purpose of this study was to characterize SARS-CoV-2 variants in patients who participated in a COVID-19 Vaccine Effectiveness and Variants (COVVAR) study at health facilities in Uganda. The study aimed to investigate the prevalence and mutation profiles of the different variant types and explore any associations between vaccination status and these variants.</p></sec><sec id="sec2-viruses-16-01860"><title>2. Materials and Methods</title><sec id="sec2dot1-viruses-16-01860"><title>2.1. Study Design and Population </title><p>The COVVAR study is a hospital-based test-negative case&#x02013;control study with the objective of estimating the effectiveness of licensed COVID-19 vaccines against laboratory-confirmed COVID-19 disease. The study was conducted by the MRC/UVRI and LSHTM Uganda Research Unit at selected health facilities in Kampala, Greater Masaka (Bukomansimbi, Kalungi, Kyotera, Lwengo, Lyantonde, Masaka, Rakai, Sembabule) and Wakiso districts. The study population included vaccine-eligible patients aged &#x02265;12 years who presented with COVID-19-like symptoms.</p></sec><sec id="sec2dot2-viruses-16-01860"><title>2.2. Case Definition and Recruitment</title><sec id="sec2dot2dot1-viruses-16-01860"><title>2.2.1. Case Definition</title><p>Any vaccine-eligible patients who presented to a designated health facility with symptoms suggestive of COVID-19 and subsequently had a positive SARS-CoV-2 real-time PCR test.</p></sec><sec id="sec2dot2dot2-viruses-16-01860"><title>2.2.2. Control Definition</title><p>Vaccine-eligible patients who presented to a designated hospital with symptoms suggestive of COVID-19 and subsequently had a negative SARS-CoV-2 real-time PCR test.</p></sec><sec id="sec2dot2dot3-viruses-16-01860"><title>2.2.3. Recruitment</title><p>Participants were recruited from outpatient clinics, emergency departments and wards of participating health facilities. A total of 1483 (55.3% female) patients with COVID-19 symptoms were screened. Of those screened, 1398 (94.3%) were enrolled between March 2023 to March 2024. The WHO case definition for identifying COVID-19-like symptoms within the last 10 days was used [<xref rid="B15-viruses-16-01860" ref-type="bibr">15</xref>]. This included persons who presented with acute onset of fever and cough or acute onset of any three or more of the following symptoms: fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnoea, anorexia, nausea, vomiting, diarrhea or altered mental status. Reasons for exclusion included having experienced symptoms for a period that exceeded more than 10 days (83, 5.6%) and being &#x0003c;12 years of age (2, 0.1%). </p></sec><sec id="sec2dot2dot4-viruses-16-01860"><title>2.2.4. Vaccination Status </title><p>Of those enrolled, 802 (57.4%) were fully vaccinated and 52 (6.5%) had received a booster vaccine dose. About the type of vaccine received, 492 (35.2%) received the Vaxzevria (Oxford University/AstraZeneca) vaccine, 288 (20.6%) received the Comirnaty (Pfizer/BioNTech) vaccine, 103 (7.4%) received the Jcovden (Johnson &#x00026; Johnson) vaccine, 33 (2.4%) received the Spikevax (Moderna) vaccine and 15 (1.1%) received the Sinopharm (Beijing Institute of Biological Products) vaccine.</p></sec></sec><sec id="sec2dot3-viruses-16-01860"><title>2.3. Sample Collection</title><p>Oropharyngeal and nasopharyngeal swabs collected from each patient as part of routine clinical care were placed in a viral transport medium (VTM) tube and transported to the MRC/UVRI and LSHTM Uganda Research Unit&#x02019;s laboratory in Entebbe for real-time PCR testing and genomic sequencing.</p></sec><sec id="sec2dot4-viruses-16-01860"><title>2.4. Data Collection </title><p>Data were collected on socio-demographics, previous COVID-19 infection, COVID-19 vaccination status and severity of current infection, and entered by trained study staff onto encrypted computers and tablets into a REDCap database. Vaccination status was captured based on self-reported data but confirmed by crosschecking the participant vaccination cards and on the Uganda Ministry of Health COVID-19 vaccination certification portal [<xref rid="B16-viruses-16-01860" ref-type="bibr">16</xref>]. Every patient record was assigned a unique study identification number and access to patient records was limited to only authorized study staff. </p></sec><sec sec-type="methods" id="sec2dot5-viruses-16-01860"><title>2.5. Laboratory Procedures and Molecular Testing</title><sec id="sec2dot5dot1-viruses-16-01860"><title>2.5.1. Nucleic Acid Extraction and Real-Time PCR</title><p>A volume of 750 &#x003bc;L of VTM eluate was used to extract RNA from nasopharyngeal swab specimens using the Nuclisens EasyMag semi-automated nucleic acid extraction platform (bioM&#x000e9;rieux, Marcy-l&#x02019;&#x000c9;toile, France) [<xref rid="B17-viruses-16-01860" ref-type="bibr">17</xref>]. Real-time PCR was performed using the Berlin [<xref rid="B18-viruses-16-01860" ref-type="bibr">18</xref>] and the Life River [<xref rid="B19-viruses-16-01860" ref-type="bibr">19</xref>] assay protocols according to the manufacturer&#x02019;s recommendations and ran on the Quant Studio <italic toggle="yes">7&#x02122; Pro</italic> Real-Time PCR System [<xref rid="B20-viruses-16-01860" ref-type="bibr">20</xref>].</p></sec><sec id="sec2dot5dot2-viruses-16-01860"><title>2.5.2. Deep Sequencing</title><p>Genomic sequencing was conducted on all SARS-CoV-2 real-time PCR-positive specimens at the MRC/UVRI &#x00026; LSHTM Uganda Research Unit&#x02019;s sequencing platform laboratories in Entebbe. Nasopharyngeal swab specimens that tested positive for SARS-CoV-2 (cycle threshold of &#x0003c;30) were sequenced using an amplicon-based next-generation sequencing (NGS) Illumina COVIDSeq kit [<xref rid="B21-viruses-16-01860" ref-type="bibr">21</xref>] on the MiSeq NGS platform [<xref rid="B22-viruses-16-01860" ref-type="bibr">22</xref>].</p></sec></sec><sec id="sec2dot6-viruses-16-01860"><title>2.6. Bioinformatic Analysis</title><p>Deep sequence FastQ paired-end reads were assembled using the EDGE Bioinformatics COVID-19 Genome analytics software version 2.4.0 [<xref rid="B23-viruses-16-01860" ref-type="bibr">23</xref>] to obtain high-quality SARS-CoV-2 genomes with &#x0003e;85% coverage. Mutation calling was performed using the Next clade software version 3.5.0 [<xref rid="B24-viruses-16-01860" ref-type="bibr">24</xref>] and SARS-CoV-2 lineage analysis was conducted using Pangolin version 4.3.1 [<xref rid="B25-viruses-16-01860" ref-type="bibr">25</xref>]. Phylogenetic analysis was performed using Iqtree version 2.3.6 [<xref rid="B26-viruses-16-01860" ref-type="bibr">26</xref>]. </p></sec></sec><sec sec-type="results" id="sec3-viruses-16-01860"><title>3. Results </title><sec id="sec3dot1-viruses-16-01860"><title>3.1. Population Characteristics </title><p>A total of 1398 participants with a median age of 30 years (interquartile range: 24&#x02013;41 years) provided nasopharyngeal swabs. The gender distribution was 44.6% males and 55.4% females. Most participants displayed typical COVID-19 symptoms, including fever (&#x0003e;38 &#x000b0;C, 70.4%), cough (89.6%), malaise (68.3%), headache (81.4%), fatigue (68.3%), and others such as shortness of breath (31.1%), loss of smell (37.7%), and chills (40.4%). </p></sec><sec id="sec3dot2-viruses-16-01860"><title>3.2. SARS-CoV-2 Lineage Analysis </title><p>Of the 1398 samples tested on real-time PCR, 174 tested positive for SARS-CoV-2 (12.4% positivity rate). Of the SARS-CoV-2 positive samples, 163 were successfully genotyped (94% success rate). All the genotyped sequences were identified as belonging to the Omicron variant. The most prevalent lineages and sublineages were XBB.1* (113 sequences, 69.3%), followed by JN.1* (12 sequences, 7.4%), XBB.2* (11 sequences, 6.7%) and FL* (11 sequences, 6.7%), EG* (7 sequences, 4.3%), with smaller numbers in other categories: 5 sequences (3.1%) classified as &#x02018;others&#x02019; and 4 sequences (2.5%) classified as CM* (2.5%) (<xref rid="viruses-16-01860-t001" ref-type="table">Table 1</xref>). </p><p>The distribution of SARS-CoV-2 lineages over time showed the dominance of the XBB.1 lineage from April 2023 to July 2023 (<xref rid="viruses-16-01860-f001" ref-type="fig">Figure 1</xref>). After that, there was a general decline in the number of SARS-CoV-2 positive cases at the study sites with almost none sampled between August and September 2023. However, from December 2023, the first JN.1 lineage was detected followed by an increase in the number of JN.1 identified.</p><p>The participants&#x02019; (COVID-19 positive individuals) vaccination status was detailed as follows: 107 (65.6%) were vaccinated (received one or more COVID-19 vaccine doses), 53 (32.5%) were not vaccinated and 3 (1.8%) had an unknown vaccination status. Genotyping results showed that 68.2% (73/107) of vaccinated and 69.8% (37/53) of non-vaccinated individuals were assigned the XBB.1 SARS-CoV-2 lineage relative to other detected lineages (<xref rid="viruses-16-01860-f002" ref-type="fig">Figure 2</xref>). The association between vaccination status and lineage assignment was assessed using Fisher&#x02019;s exact test. There was no statistically significant association between vaccination status and lineage assignment (<italic toggle="yes">p</italic>-value = 0.994). </p></sec><sec id="sec3dot3-viruses-16-01860"><title>3.3. Mutation Analysis </title><p>Analysis in Nextclade [<xref rid="B24-viruses-16-01860" ref-type="bibr">24</xref>] based on the Wuhan-Hu-1/2019 (MN908947) reference sequence, identified several mutations in the spike protein region (<xref rid="app1-viruses-16-01860" ref-type="app">Supplementary Table S1</xref>) that included the T19I, A27S, H655Y, N679K, N969K and D614G as the most frequent mutations detected. The distribution of identified nucleotide and amino acid mutations across various lineages is shown in <xref rid="viruses-16-01860-f003" ref-type="fig">Figure 3</xref>. The D614G point mutation has been associated with increased infectivity and replication fitness compared to the original SARS-CoV-2 [<xref rid="B27-viruses-16-01860" ref-type="bibr">27</xref>,<xref rid="B28-viruses-16-01860" ref-type="bibr">28</xref>]. The JN.1 omicron variant lineage had the highest number of nucleotide mutations compared to any other variant identified in this study with spike protein mutations that included the R21T, S50L, V127F, R158G as well as the L455S. The JN.1 variant&#x02019;s increased transmissibility and immune evasion potential have been attributed to these mutations [<xref rid="B6-viruses-16-01860" ref-type="bibr">6</xref>,<xref rid="B29-viruses-16-01860" ref-type="bibr">29</xref>]. Notably, a distinctive L455S mutation in the spike protein sets JN.1 apart from its parent lineage, BA.2.86 [<xref rid="B30-viruses-16-01860" ref-type="bibr">30</xref>].</p><p>We retrieved 206 Ugandan sequences from GISAID (spanning a period of 2023&#x02013;2024) to supplement those generated from the COVVAR study. A multiple sequence alignment was generated using MAFFT [<xref rid="B31-viruses-16-01860" ref-type="bibr">31</xref>]. We reconstructed a maximum likelihood phylogenetic tree (<xref rid="viruses-16-01860-f004" ref-type="fig">Figure 4</xref>) using IQ-TREE [<xref rid="B26-viruses-16-01860" ref-type="bibr">26</xref>] based on a GTR+F+R2 model of nucleotide substitution chosen as the optimum model using the Jmodel test [<xref rid="B32-viruses-16-01860" ref-type="bibr">32</xref>]. The phylogenetic tree was visualized using phytools [<xref rid="B33-viruses-16-01860" ref-type="bibr">33</xref>] and ggtreeExtra packages in R [<xref rid="B34-viruses-16-01860" ref-type="bibr">34</xref>]. Phylogenetic analysis showed that XBB* SARS-CoV-2 lineages and sublineages constituted the majority of Ugandan sequences generated from both the COVVAR study and GISAID database. However, the JN.1 lineage formed a separate monophyletic cluster on the phylogenetic tree for sequences generated from the COVVAR study and those deposited in GISAID, highlighting its substantial genetic and evolutionary divergence relative to other SARS-CoV-2 lineages that could be attributed to its notable spike protein mutation profile.</p></sec></sec><sec sec-type="discussion" id="sec4-viruses-16-01860"><title>4. Discussion</title><p>In our study, we identified the Omicron XBB.1 lineage and its sub-lineages as the most dominant, which is consistent with the findings of other studies carried out globally in 2023 [<xref rid="B35-viruses-16-01860" ref-type="bibr">35</xref>,<xref rid="B36-viruses-16-01860" ref-type="bibr">36</xref>,<xref rid="B37-viruses-16-01860" ref-type="bibr">37</xref>]. This dominance can be attributed to the heightened immune evasion capabilities acquired by variants within this lineage [<xref rid="B37-viruses-16-01860" ref-type="bibr">37</xref>]. The XBB lineage, identified in September 2022, originated through the recombination of two BA.2-derived variants, gradually supplanting pre-existing Omicron strains. Characterized by heightened transmissibility rates and immune evasion properties, members of the XBB lineage have been responsible for initiating small waves of infections across numerous countries, albeit with a heterogeneous geographical distribution. For instance, the subvariant XBB.1.5 colloquially referred to as &#x0201c;Kraken&#x0201d; has been the prevailing strain for the majority of 2023 [<xref rid="B38-viruses-16-01860" ref-type="bibr">38</xref>].</p><p>Notably, the emergence of the JN.1 sub-lineage has rapidly replaced other strains to become predominant in multiple countries, demonstrating its competitive advantage [<xref rid="B39-viruses-16-01860" ref-type="bibr">39</xref>]. The presence of other subvariants, such as XBB.2, EG.5.2, and JN.1, detected at smaller proportions, underscores the genetic diversity within the Omicron lineage. While these variants were present at low frequencies, their detection emphasizes the importance of continued genomic surveillance to monitor the emergence and circulation of novel variants [<xref rid="B38-viruses-16-01860" ref-type="bibr">38</xref>,<xref rid="B40-viruses-16-01860" ref-type="bibr">40</xref>]. Understanding the prevalence and distribution of these lineages and sub-lineages could inform public health strategies, such as vaccine development and surveillance efforts [<xref rid="B41-viruses-16-01860" ref-type="bibr">41</xref>,<xref rid="B42-viruses-16-01860" ref-type="bibr">42</xref>]. It was also noteworthy that a small proportion of samples exhibited variants such as the EG.5&#x02014;also known as &#x02018;Eris&#x02019;, a variant that emerged around February 2023 and rapidly spread in over 50 countries&#x02014;and BA.2.86, the ancestral virus of the JN.1. The BA.2.86 has about 60 more spike protein mutations than the original or parent virus and over 30 more mutations than its close Omicron relatives, the BA.2 and earlier dominant XBB.1.5 variant. </p><p>The JN.1 spread rapidly to become the most widely circulating lineage in the United States and accounted for more than 80% of all circulating variants by the end of January 2024 [<xref rid="B43-viruses-16-01860" ref-type="bibr">43</xref>]. It has established itself as the dominant global strain [<xref rid="B44-viruses-16-01860" ref-type="bibr">44</xref>]. To date, only 18 JN.1* SARS-CoV-2 Omicron sub-variant cases have been reported in Uganda in GISAID [<xref rid="B45-viruses-16-01860" ref-type="bibr">45</xref>]. Several VoC SARS-CoV-2 mutations that included E484K and P681R were initially identified in the Alpha and Beta variants in early 2021. It is unknown why those mutations were not detected in the Omicron family of viruses but returned in the JN.1 Omicron lineage. In Uganda, more extensive genomic surveillance is needed to assess the extent of spread of JN.1 as well as monitor other SARS-CoV-2 variants that are currently circulating to inform prevention efforts. Recent genotyping of community samples in Uganda conducted between May and June 2024 has shown that over 90% of identified lineages and sub-lineages belong to the JN.1* of SARS-CoV-2 (unpublished data). This highlights the virus&#x02019; fitness to outcompete previously dominant lineages. Genomic sequencing plays a key role in monitoring the evolution of the SARS-CoV-2 genome and provides information on the genetic characteristics of recently circulating or dominant SARS-CoV-2 strains that is critical for COVID-19 vaccine design research. </p></sec><sec sec-type="conclusions" id="sec5-viruses-16-01860"><title>5. Conclusions</title><p>Overall, genotypic data showed that the Omicron variant, particularly the XBB.1 lineage, was predominant until July 2023. Since then, other lineages and sub-lineages of the JN.1 variant have been increasingly detected and designated as variants of interest as of 3 May 2024 [<xref rid="B46-viruses-16-01860" ref-type="bibr">46</xref>]. Our results contribute to an understanding of the genetic diversity and distribution of Omicron subvariants within the analyzed population. Further comparative analysis with additional datasets and ongoing genomic surveillance efforts will be crucial for tracking the evolution and spread of SARS-CoV-2 variants, informing effective public health responses. As JN.1 continues to evolve and is poised to replace the XBB.1 sublineage, ongoing surveillance, vaccination strategies, and adherence to preventive measures are crucial to mitigating its potential impact on global public health. A limitation of this study was the small number of positive samples as a result of the declining number of SARS-CoV-2 positive cases at the study sites, particularly after July 2023. However, despite the small sample size, the study identified important trends in the evolution of SARS-CoV-2 variants in Uganda including the appearance and increased prevalence of the JN.1 variant. </p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to acknowledge the study participants, study staff, and heads of health facilities from where the study participants were enrolled and samples collected.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-viruses-16-01860"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/v16121860/s1">https://www.mdpi.com/article/10.3390/v16121860/s1</uri>. Table S1: Detailed nucleotide and amino acid mutation list.</p><supplementary-material id="viruses-16-01860-s001" position="float" content-type="local-data"><media xlink:href="viruses-16-01860-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, P.K., E.R., D.S., A.M.E., A.A. and S.K.; methodology, R.K., H.S.N., S.E.N., D.K. and C.R.; software, N.B. and A.S.; validation, N.B., A.S. and D.S.; formal analysis, N.B. and A.S.; investigation, N.B. and D.S.; resources, S.K., E.R. and P.K.; data curation, N.B. and A.S.; writing&#x02014;original draft preparation, N.B.; writing&#x02014;review and editing, A.K. (Annet Kisakye), Y.T.W., S.K., T.A.O., A.K. (Ayoub Kakande), A.A., G.K., H.K.B., A.D., J.M.M., A.K.W., J.H., S.C., A.M.E., E.R., P.K. and D.S.; visualization, A.A. and A.S.; supervision, E.R., P.K. and D.S.; project administration, S.K.; funding acquisition, A.A., E.R., A.M.E., P.K. and D.S. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The COVVAR study was approved by the Uganda Virus Research Institute Research Ethics Committee (Ref # GC/127/952, 22 February 2023), the Uganda National Council of Science and Technology (Ref # HS2672ES, 7 March 2023) and the London School of Hygiene and Tropical Medicine, Research Ethics Committee (Ref#-28824, 16 March 2023). Administrative approvals were obtained from the Uganda Ministry of Health and all participating hospitals/health facilities.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained. Written informed consent and assent (for persons aged less than 18 years) was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>All SARS-CoV-2 nucleotide sequence data are available and have been deposited in the GISAID database and is publicly available with the following accession numbers: EPI_ISL_19139431-19139566, EPI_ISL_19139747-19139765 and EPI_ISL_19164604-19164611.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Mr. James Humphreys and Dr. Sandra Cohuet are affiliated to the Epiconcept company, Paris, France and have no part in funding the study. The authors therefore declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01860"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bugembe</surname><given-names>D.L.</given-names></name>
<name><surname>Kayiwa</surname><given-names>J.</given-names></name>
<name><surname>Phan</surname><given-names>M.V.T.</given-names></name>
<name><surname>Tushabe</surname><given-names>P.</given-names></name>
<name><surname>Balinandi</surname><given-names>S.</given-names></name>
<name><surname>Dhaala</surname><given-names>B.</given-names></name>
<name><surname>Lexow</surname><given-names>J.</given-names></name>
<name><surname>Mwebesa</surname><given-names>H.</given-names></name>
<name><surname>Aceng</surname><given-names>J.</given-names></name>
<name><surname>Kyobe</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Main Routes of Entry and Genomic Diversity of SARS-CoV-2, Uganda</article-title><source>Emerg. Infect. Dis.</source><year>2020</year><volume>26</volume><fpage>2411</fpage><lpage>2415</lpage><pub-id pub-id-type="doi">10.3201/eid2610.202575</pub-id><pub-id pub-id-type="pmid">32614767</pub-id>
</element-citation></ref><ref id="B2-viruses-16-01860"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bugembe</surname><given-names>D.L.</given-names></name>
<name><surname>Phan</surname><given-names>M.V.T.</given-names></name>
<name><surname>Ssewanyana</surname><given-names>I.</given-names></name>
<name><surname>Semanda</surname><given-names>P.</given-names></name>
<name><surname>Nansumba</surname><given-names>H.</given-names></name>
<name><surname>Dhaala</surname><given-names>B.</given-names></name>
<name><surname>Nabadda</surname><given-names>S.</given-names></name>
<name><surname>O&#x02019;Toole</surname><given-names>&#x000c1;.N.</given-names></name>
<name><surname>Rambaut</surname><given-names>A.</given-names></name>
<name><surname>Kaleebu</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Emergence and Spread of a SARS-CoV-2 Lineage A Variant (A.23.1) with Altered Spike Protein in Uganda</article-title><source>Nat. Microbiol.</source><year>2021</year><volume>6</volume><fpage>1094</fpage><lpage>1101</lpage><pub-id pub-id-type="doi">10.1038/s41564-021-00933-9</pub-id><pub-id pub-id-type="pmid">34163035</pub-id>
</element-citation></ref><ref id="B3-viruses-16-01860"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bbosa</surname><given-names>N.</given-names></name>
<name><surname>Ssemwanga</surname><given-names>D.</given-names></name>
<name><surname>Namagembe</surname><given-names>H.</given-names></name>
<name><surname>Kiiza</surname><given-names>R.</given-names></name>
<name><surname>Kiconco</surname><given-names>J.</given-names></name>
<name><surname>Kayiwa</surname><given-names>J.</given-names></name>
<name><surname>Lutalo</surname><given-names>T.</given-names></name>
<name><surname>Lutwama</surname><given-names>J.</given-names></name>
<name><surname>Ssekagiri</surname><given-names>A.</given-names></name>
<name><surname>Ssewanyana</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>Rapid Replacement of SARS-CoV-2 Variants by Delta and Subsequent Arrival of Omicron, Uganda, 2021</article-title><source>Emerg. Infect. Dis.</source><year>2022</year><volume>28</volume><fpage>1021</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.3201/eid2805.220121</pub-id><pub-id pub-id-type="pmid">35320700</pub-id>
</element-citation></ref><ref id="B4-viruses-16-01860"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Thakur</surname><given-names>V.</given-names></name>
<name><surname>Ratho</surname><given-names>R.K.</given-names></name>
</person-group><article-title>OMICRON (B.1.1.529): A New SARS-CoV-2 Variant of Concern Mounting Worldwide Fear</article-title><source>J. Med. Virol.</source><year>2022</year><volume>94</volume><fpage>1821</fpage><lpage>1824</lpage><pub-id pub-id-type="doi">10.1002/jmv.27541</pub-id><pub-id pub-id-type="pmid">34936120</pub-id>
</element-citation></ref><ref id="B5-viruses-16-01860"><label>5.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization (WHO)</collab>
</person-group><article-title>Updated Risk Evaluation of JN.1, 15 April 2024</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/docs/default-source/coronaviruse/15042024_jn1_ure.pdf" ext-link-type="uri">https://www.who.int/docs/default-source/coronaviruse/15042024_jn1_ure.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-11-22">(accessed on 22 November 2024)</date-in-citation></element-citation></ref><ref id="B6-viruses-16-01860"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaku</surname><given-names>Y.</given-names></name>
<name><surname>Okumura</surname><given-names>K.</given-names></name>
<name><surname>Padilla-Blanco</surname><given-names>M.</given-names></name>
<name><surname>Kosugi</surname><given-names>Y.</given-names></name>
<name><surname>Uriu</surname><given-names>K.</given-names></name>
<name><surname>Hinay</surname><given-names>A.A.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Plianchaisuk</surname><given-names>A.</given-names></name>
<name><surname>Kobiyama</surname><given-names>K.</given-names></name>
<name><surname>Ishii</surname><given-names>K.J.</given-names></name>
<etal/>
</person-group><article-title>Virological Characteristics of the SARS-CoV-2 JN.1 Variant</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>e82</fpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00813-7</pub-id><pub-id pub-id-type="pmid">38184005</pub-id>
</element-citation></ref><ref id="B7-viruses-16-01860"><label>7.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization (WHO)</collab>
</person-group><article-title>Tracking SARS-CoV-2 Variants</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/activities/tracking-SARS-CoV-2-variants" ext-link-type="uri">https://www.who.int/activities/tracking-SARS-CoV-2-variants</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-13">(accessed on 13 May 2024)</date-in-citation></element-citation></ref><ref id="B8-viruses-16-01860"><label>8.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization (WHO)</collab>
</person-group><article-title>Enhancing Readiness for Omicron (B.1.1.529)</article-title><comment>Available online: <ext-link xlink:href="https://www.who.int/docs/default-source/coronaviruse/2021-12-23-global-technical-brief-and-priority-action-on-omicron.pdf" ext-link-type="uri">https://www.who.int/docs/default-source/coronaviruse/2021-12-23-global-technical-brief-and-priority-action-on-omicron.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-15">(accessed on 15 May 2024)</date-in-citation></element-citation></ref><ref id="B9-viruses-16-01860"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sah</surname><given-names>P.</given-names></name>
<name><surname>Vilches</surname><given-names>T.N.</given-names></name>
<name><surname>Pandey</surname><given-names>A.</given-names></name>
<name><surname>Schneider</surname><given-names>E.C.</given-names></name>
<name><surname>Moghadas</surname><given-names>S.M.</given-names></name>
<name><surname>Galvani</surname><given-names>A.P.</given-names></name>
</person-group><article-title>Estimating the Impact of Vaccination on Reducing COVID-19 Burden in the United States: December 2020 to March 2022</article-title><source>J. Glob. Health</source><year>2022</year><volume>12</volume><fpage>03062</fpage><pub-id pub-id-type="doi">10.7189/jogh.12.03062</pub-id><pub-id pub-id-type="pmid">36056814</pub-id>
</element-citation></ref><ref id="B10-viruses-16-01860"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Calabr&#x000f2;</surname><given-names>G.E.</given-names></name>
<name><surname>Pappalardo</surname><given-names>C.</given-names></name>
<name><surname>D&#x02019;Ambrosio</surname><given-names>F.</given-names></name>
<name><surname>Vece</surname><given-names>M.</given-names></name>
<name><surname>Lupi</surname><given-names>C.</given-names></name>
<name><surname>Lontano</surname><given-names>A.</given-names></name>
<name><surname>Di Russo</surname><given-names>M.</given-names></name>
<name><surname>Ricciardi</surname><given-names>R.</given-names></name>
<name><surname>de Waure</surname><given-names>C.</given-names></name>
</person-group><article-title>The Impact of Vaccination on COVID-19 Burden of Disease in the Adult and Elderly Population: A Systematic Review of Italian Evidence</article-title><source>Vaccines</source><year>2023</year><volume>11</volume><elocation-id>1011</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines11051011</pub-id><pub-id pub-id-type="pmid">37243115</pub-id>
</element-citation></ref><ref id="B11-viruses-16-01860"><label>11.</label><element-citation publication-type="webpage"><article-title>COVID19 Vaccine Tracker</article-title><comment>Available online: <ext-link xlink:href="https://covid19.trackvaccines.org/country/uganda/" ext-link-type="uri">https://covid19.trackvaccines.org/country/uganda/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-13">(accessed on 13 May 2024)</date-in-citation></element-citation></ref><ref id="B12-viruses-16-01860"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>King</surname><given-names>A.P.</given-names></name>
<name><surname>Wanyana</surname><given-names>M.W.</given-names></name>
<name><surname>Migisha</surname><given-names>R.</given-names></name>
<name><surname>Kadobera</surname><given-names>D.</given-names></name>
<name><surname>Kwesiga</surname><given-names>B.</given-names></name>
<name><surname>Biribawa</surname><given-names>C.</given-names></name>
</person-group><article-title>COVID-19 Vaccine Uptake and Coverage, Uganda, 2021&#x02013;2022</article-title><source>Uganda Natl. Inst. Public Health Q. Epidemiol. Bull.</source><year>2023</year><volume>8</volume><fpage>18</fpage><lpage>29</lpage></element-citation></ref><ref id="B13-viruses-16-01860"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dubey</surname><given-names>A.</given-names></name>
<name><surname>Choudhary</surname><given-names>S.</given-names></name>
<name><surname>Kumar</surname><given-names>P.</given-names></name>
<name><surname>Tomar</surname><given-names>S.</given-names></name>
</person-group><article-title>Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications</article-title><source>Curr. Microbiol.</source><year>2022</year><volume>79</volume><elocation-id>20</elocation-id><pub-id pub-id-type="doi">10.1007/s00284-021-02724-1</pub-id></element-citation></ref><ref id="B14-viruses-16-01860"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dingemans</surname><given-names>J.</given-names></name>
<name><surname>van der Veer</surname><given-names>B.M.J.W.</given-names></name>
<name><surname>Gorgels</surname><given-names>K.M.F.</given-names></name>
<name><surname>Hackert</surname><given-names>V.</given-names></name>
<name><surname>den Heijer</surname><given-names>C.D.J.</given-names></name>
<name><surname>Hoebe</surname><given-names>C.J.P.A.</given-names></name>
<name><surname>Savelkoul</surname><given-names>P.H.M.</given-names></name>
<name><surname>van Alphen</surname><given-names>L.B.</given-names></name>
</person-group><article-title>Investigating SARS-CoV-2 Breakthrough Infections per Variant and Vaccine Type</article-title><source>Front. Microbiol.</source><year>2022</year><volume>13</volume><elocation-id>1027271</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2022.1027271</pub-id><pub-id pub-id-type="pmid">36504818</pub-id>
</element-citation></ref><ref id="B15-viruses-16-01860"><label>15.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization (WHO)</collab>
</person-group><article-title>COVID-19 Case Definitions 2022</article-title><comment>Available online: <ext-link xlink:href="http://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2022-1/" ext-link-type="uri">http://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2022-1/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-15">(accessed on 15 May 2024)</date-in-citation></element-citation></ref><ref id="B16-viruses-16-01860"><label>16.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>Ministry of Health Uganda</collab>
</person-group><article-title>Uganda National COVID-19 Vaccination Certification Portal</article-title><comment>Available online: <ext-link xlink:href="https://epivac.health.go.ug/certificates/" ext-link-type="uri">https://epivac.health.go.ug/certificates/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-10-09">(accessed on 9 October 2024)</date-in-citation></element-citation></ref><ref id="B17-viruses-16-01860"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hindiyeh</surname><given-names>M.</given-names></name>
<name><surname>Mor</surname><given-names>O.</given-names></name>
<name><surname>Pando</surname><given-names>R.</given-names></name>
<name><surname>Mannasse</surname><given-names>B.</given-names></name>
<name><surname>Kabat</surname><given-names>A.</given-names></name>
<name><surname>Assraf-Zarfati</surname><given-names>H.</given-names></name>
<name><surname>Mendelson</surname><given-names>E.</given-names></name>
<name><surname>Sofer</surname><given-names>D.</given-names></name>
<name><surname>Mandelboim</surname><given-names>M.</given-names></name>
</person-group><article-title>Comparison of the New Fully Automated Extraction Platform eMAG to the MagNA PURE 96 and the Well-Established easyMAG for Detection of Common Human Respiratory Viruses</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0211079</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0211079</pub-id><pub-id pub-id-type="pmid">30779757</pub-id>
</element-citation></ref><ref id="B18-viruses-16-01860"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Corman</surname><given-names>V.</given-names></name>
<name><surname>Bleicker</surname><given-names>T.</given-names></name>
<name><surname>Br&#x000fc;nink</surname><given-names>S.</given-names></name>
<name><surname>Drosten</surname><given-names>C.</given-names></name>
<name><surname>Zambon</surname><given-names>M.</given-names></name>
</person-group><article-title>Diagnostic Detection of 2019-nCoV by Real-Time RT-PCR</article-title><source>World Health Organ.</source><year>2020</year><volume>17</volume><fpage>1</fpage><lpage>13</lpage></element-citation></ref><ref id="B19-viruses-16-01860"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Linkowska</surname><given-names>K.</given-names></name>
<name><surname>Bogiel</surname><given-names>T.</given-names></name>
<name><surname>Lamperska</surname><given-names>K.</given-names></name>
<name><surname>Marsza&#x00142;ek</surname><given-names>A.</given-names></name>
<name><surname>Starzy&#x00144;ski</surname><given-names>J.</given-names></name>
<name><surname>Szylberg</surname><given-names>&#x00141;.</given-names></name>
<name><surname>Szwed-Kowalska</surname><given-names>A.</given-names></name>
<name><surname>Paw&#x00142;owska</surname><given-names>M.</given-names></name>
<name><surname>Grzybowski</surname><given-names>T.</given-names></name>
</person-group><article-title>Commercially Available SARS-CoV-2 RT-qPCR Diagnostic Tests Need Obligatory Internal Validation</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>6991</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-34220-w</pub-id><pub-id pub-id-type="pmid">37117538</pub-id>
</element-citation></ref><ref id="B20-viruses-16-01860"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hole</surname><given-names>K.</given-names></name>
<name><surname>Nfon</surname><given-names>C.</given-names></name>
<name><surname>Rodriguez</surname><given-names>L.L.</given-names></name>
<name><surname>Velazquez-Salinas</surname><given-names>L.</given-names></name>
</person-group><article-title>A Multiplex Real-Time Reverse Transcription Polymerase Chain Reaction Assay With Enhanced Capacity to Detect Vesicular Stomatitis Viral Lineages of Central American Origin</article-title><source>Front. Vet. Sci.</source><year>2021</year><volume>8</volume><elocation-id>783198</elocation-id><pub-id pub-id-type="doi">10.3389/fvets.2021.783198</pub-id><pub-id pub-id-type="pmid">34988142</pub-id>
</element-citation></ref><ref id="B21-viruses-16-01860"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lowry</surname><given-names>K.</given-names></name>
<name><surname>Bauer</surname><given-names>M.J.</given-names></name>
<name><surname>Buckley</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>C.</given-names></name>
<name><surname>Bordin</surname><given-names>A.</given-names></name>
<name><surname>Badman</surname><given-names>S.</given-names></name>
<name><surname>Harris</surname><given-names>P.N.</given-names></name>
<name><surname>Mackay</surname><given-names>I.</given-names></name>
<name><surname>Whiley</surname><given-names>D.</given-names></name>
</person-group><article-title>Evaluation of Illumina<sup>&#x000ae;</sup> COVIDSeq<sup>TM</sup> as a Tool for Omicron SARS-CoV-2 Characterisation</article-title><source>J. Virol. Methods</source><year>2023</year><volume>322</volume><fpage>114827</fpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2023.114827</pub-id><pub-id pub-id-type="pmid">37778540</pub-id>
</element-citation></ref><ref id="B22-viruses-16-01860"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shokralla</surname><given-names>S.</given-names></name>
<name><surname>Porter</surname><given-names>T.M.</given-names></name>
<name><surname>Gibson</surname><given-names>J.F.</given-names></name>
<name><surname>Dobosz</surname><given-names>R.</given-names></name>
<name><surname>Janzen</surname><given-names>D.H.</given-names></name>
<name><surname>Hallwachs</surname><given-names>W.</given-names></name>
<name><surname>Golding</surname><given-names>G.B.</given-names></name>
<name><surname>Hajibabaei</surname><given-names>M.</given-names></name>
</person-group><article-title>Massively Parallel Multiplex DNA Sequencing for Specimen Identification Using an Illumina MiSeq Platform</article-title><source>Sci. Rep.</source><year>2015</year><volume>5</volume><elocation-id>9687</elocation-id><pub-id pub-id-type="doi">10.1038/srep09687</pub-id><pub-id pub-id-type="pmid">25884109</pub-id>
</element-citation></ref><ref id="B23-viruses-16-01860"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lo</surname><given-names>C.-C.</given-names></name>
<name><surname>Shakya</surname><given-names>M.</given-names></name>
<name><surname>Connor</surname><given-names>R.</given-names></name>
<name><surname>Davenport</surname><given-names>K.</given-names></name>
<name><surname>Flynn</surname><given-names>M.</given-names></name>
<name><surname>Guti&#x000e9;rrez</surname><given-names>A.M.</given-names></name>
<name><surname>Hu</surname><given-names>B.</given-names></name>
<name><surname>Li</surname><given-names>P.-E.</given-names></name>
<name><surname>Jackson</surname><given-names>E.P.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
</person-group><article-title>EDGE COVID-19: A Web Platform to Generate Submission-Ready Genomes from SARS-CoV-2 Sequencing Efforts</article-title><source>Bioinformatics</source><year>2022</year><volume>38</volume><fpage>2700</fpage><lpage>2704</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btac176</pub-id><pub-id pub-id-type="pmid">35561186</pub-id>
</element-citation></ref><ref id="B24-viruses-16-01860"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aksamentov</surname><given-names>I.</given-names></name>
<name><surname>Roemer</surname><given-names>C.</given-names></name>
<name><surname>Hodcroft</surname><given-names>E.B.</given-names></name>
<name><surname>Neher</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Nextclade: Clade Assignment, Mutation Calling and Quality Control for Viral Genomes</article-title><source>J. Open Source Softw.</source><year>2021</year><volume>6</volume><fpage>3773</fpage><pub-id pub-id-type="doi">10.21105/joss.03773</pub-id></element-citation></ref><ref id="B25-viruses-16-01860"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Toole</surname><given-names>&#x000c1;.</given-names></name>
<name><surname>Scher</surname><given-names>E.</given-names></name>
<name><surname>Underwood</surname><given-names>A.</given-names></name>
<name><surname>Jackson</surname><given-names>B.</given-names></name>
<name><surname>Hill</surname><given-names>V.</given-names></name>
<name><surname>McCrone</surname><given-names>J.T.</given-names></name>
<name><surname>Colquhoun</surname><given-names>R.</given-names></name>
<name><surname>Ruis</surname><given-names>C.</given-names></name>
<name><surname>Abu-Dahab</surname><given-names>K.</given-names></name>
<name><surname>Taylor</surname><given-names>B.</given-names></name>
</person-group><article-title>Assignment of Epidemiological Lineages in an Emerging Pandemic Using the Pangolin Tool</article-title><source>Virus Evol.</source><year>2021</year><volume>7</volume><fpage>veab064</fpage><pub-id pub-id-type="doi">10.1093/ve/veab064</pub-id><pub-id pub-id-type="pmid">34527285</pub-id>
</element-citation></ref><ref id="B26-viruses-16-01860"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nguyen</surname><given-names>L.-T.</given-names></name>
<name><surname>Schmidt</surname><given-names>H.A.</given-names></name>
<name><surname>von Haeseler</surname><given-names>A.</given-names></name>
<name><surname>Minh</surname><given-names>B.Q.</given-names></name>
</person-group><article-title>IQ-TREE: A Fast and Effective Stochastic Algorithm for Estimating Maximum-Likelihood Phylogenies</article-title><source>Mol. Biol. Evol.</source><year>2015</year><volume>32</volume><fpage>268</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1093/molbev/msu300</pub-id><pub-id pub-id-type="pmid">25371430</pub-id>
</element-citation></ref><ref id="B27-viruses-16-01860"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>F.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Guo</surname><given-names>W.</given-names></name>
<name><surname>Zhou</surname><given-names>X.</given-names></name>
<name><surname>Feng</surname><given-names>K.</given-names></name>
<name><surname>Huang</surname><given-names>T.</given-names></name>
<name><surname>Cai</surname><given-names>Y.</given-names></name>
</person-group><article-title>Identifying COVID-19 Severity-Related SARS-CoV-2 Mutation Using a Machine Learning Method</article-title><source>Life</source><year>2022</year><volume>12</volume><elocation-id>806</elocation-id><pub-id pub-id-type="doi">10.3390/life12060806</pub-id><pub-id pub-id-type="pmid">35743837</pub-id>
</element-citation></ref><ref id="B28-viruses-16-01860"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Korber</surname><given-names>B.</given-names></name>
<name><surname>Fischer</surname><given-names>W.M.</given-names></name>
<name><surname>Gnanakaran</surname><given-names>S.</given-names></name>
<name><surname>Yoon</surname><given-names>H.</given-names></name>
<name><surname>Theiler</surname><given-names>J.</given-names></name>
<name><surname>Abfalterer</surname><given-names>W.</given-names></name>
<name><surname>Hengartner</surname><given-names>N.</given-names></name>
<name><surname>Giorgi</surname><given-names>E.E.</given-names></name>
<name><surname>Bhattacharya</surname><given-names>T.</given-names></name>
<name><surname>Foley</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Tracking Changes in SARS-CoV-2 Spike: Evidence That D614G Increases Infectivity of the COVID-19 Virus</article-title><source>Cell</source><year>2020</year><volume>182</volume><fpage>812</fpage><lpage>827.e19</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.06.043</pub-id><pub-id pub-id-type="pmid">32697968</pub-id>
</element-citation></ref><ref id="B29-viruses-16-01860"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kamble</surname><given-names>P.</given-names></name>
<name><surname>Daulatabad</surname><given-names>V.</given-names></name>
<name><surname>Singhal</surname><given-names>A.</given-names></name>
<name><surname>Ahmed</surname><given-names>Z.S.</given-names></name>
<name><surname>Choubey</surname><given-names>A.</given-names></name>
<name><surname>Bhargava</surname><given-names>S.</given-names></name>
<name><surname>John</surname><given-names>N.A.</given-names></name>
</person-group><article-title>JN.1 Variant in Enduring COVID-19 Pandemic: Is It a Variety of Interest (VoI) or Variety of Concern (VoC)?</article-title><source>Horm. Mol. Biol. Clin. Investig.</source><year>2024</year><volume>45</volume><fpage>49</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1515/hmbci-2023-0088</pub-id></element-citation></ref><ref id="B30-viruses-16-01860"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hemo</surname><given-names>M.K.</given-names></name>
<name><surname>Islam</surname><given-names>M.A.</given-names></name>
</person-group><article-title>JN.1 as a New Variant of COVID-19&#x02013;Editorial</article-title><source>Ann. Med. Surg.</source><year>2024</year><volume>86</volume><fpage>1833</fpage><lpage>1835</lpage><pub-id pub-id-type="doi">10.1097/MS9.0000000000001876</pub-id><pub-id pub-id-type="pmid">38576941</pub-id>
</element-citation></ref><ref id="B31-viruses-16-01860"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Katoh</surname><given-names>K.</given-names></name>
<name><surname>Standley</surname><given-names>D.M.</given-names></name>
</person-group><article-title>MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability</article-title><source>Mol. Biol. Evol.</source><year>2013</year><volume>30</volume><fpage>772</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1093/molbev/mst010</pub-id><pub-id pub-id-type="pmid">23329690</pub-id>
</element-citation></ref><ref id="B32-viruses-16-01860"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Posada</surname><given-names>D.</given-names></name>
</person-group><article-title>jModelTest: Phylogenetic Model Averaging</article-title><source>Mol. Biol. Evol.</source><year>2008</year><volume>25</volume><fpage>1253</fpage><lpage>1256</lpage><pub-id pub-id-type="doi">10.1093/molbev/msn083</pub-id><pub-id pub-id-type="pmid">18397919</pub-id>
</element-citation></ref><ref id="B33-viruses-16-01860"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Revell</surname><given-names>L.J.</given-names></name>
</person-group><article-title>phytools 2.0: An updated R ecosystem for phylogenetic comparative methods (and other things)</article-title><source>PeerJ</source><year>2024</year><volume>12</volume><fpage>e16505</fpage><pub-id pub-id-type="doi">10.7717/peerj.16505</pub-id><pub-id pub-id-type="pmid">38192598</pub-id>
</element-citation></ref><ref id="B34-viruses-16-01860"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>S.</given-names></name>
<name><surname>Dai</surname><given-names>Z.</given-names></name>
<name><surname>Guo</surname><given-names>P.</given-names></name>
<name><surname>Fu</surname><given-names>X.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Zhou</surname><given-names>L.</given-names></name>
<name><surname>Tang</surname><given-names>W.</given-names></name>
<name><surname>Feng</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Zhan</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>ggtreeExtra: Compact Visualization of Richly Annotated Phylogenetic Data</article-title><source>Mol. Biol. Evol.</source><year>2021</year><volume>38</volume><fpage>4039</fpage><lpage>4042</lpage><pub-id pub-id-type="doi">10.1093/molbev/msab166</pub-id><pub-id pub-id-type="pmid">34097064</pub-id>
</element-citation></ref><ref id="B35-viruses-16-01860"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karyakarte</surname><given-names>R.P.</given-names></name>
<name><surname>Das</surname><given-names>R.</given-names></name>
<name><surname>Dudhate</surname><given-names>S.</given-names></name>
<name><surname>Agarasen</surname><given-names>J.</given-names></name>
<name><surname>Pillai</surname><given-names>P.</given-names></name>
<name><surname>Chandankhede</surname><given-names>P.M.</given-names></name>
<name><surname>Labhshetwar</surname><given-names>R.S.</given-names></name>
<name><surname>Gadiyal</surname><given-names>Y.</given-names></name>
<name><surname>Rajmane</surname><given-names>M.V.</given-names></name>
<name><surname>Kulkarni</surname><given-names>P.P.</given-names></name>
</person-group><article-title>Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected with Omicron Subvariants and the XBB Recombinant Variant</article-title><source>Cureus</source><year>2023</year><volume>15</volume><fpage>e35261</fpage><pub-id pub-id-type="doi">10.7759/cureus.35261</pub-id><pub-id pub-id-type="pmid">36968876</pub-id>
</element-citation></ref><ref id="B36-viruses-16-01860"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zabidi</surname><given-names>N.Z.</given-names></name>
<name><surname>Liew</surname><given-names>H.L.</given-names></name>
<name><surname>Farouk</surname><given-names>I.A.</given-names></name>
<name><surname>Puniyamurti</surname><given-names>A.</given-names></name>
<name><surname>Yip</surname><given-names>A.J.W.</given-names></name>
<name><surname>Wijesinghe</surname><given-names>V.N.</given-names></name>
<name><surname>Low</surname><given-names>Z.Y.</given-names></name>
<name><surname>Tang</surname><given-names>J.W.</given-names></name>
<name><surname>Chow</surname><given-names>V.T.</given-names></name>
<name><surname>Lal</surname><given-names>S.K.</given-names></name>
</person-group><article-title>Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>944</elocation-id><pub-id pub-id-type="doi">10.3390/v15040944</pub-id><pub-id pub-id-type="pmid">37112923</pub-id>
</element-citation></ref><ref id="B37-viruses-16-01860"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Qu</surname><given-names>P.</given-names></name>
<name><surname>Faraone</surname><given-names>J.N.</given-names></name>
<name><surname>Evans</surname><given-names>J.P.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.-M.</given-names></name>
<name><surname>Carlin</surname><given-names>C.</given-names></name>
<name><surname>Anghelina</surname><given-names>M.</given-names></name>
<name><surname>Stevens</surname><given-names>P.</given-names></name>
<name><surname>Fernandez</surname><given-names>S.</given-names></name>
<name><surname>Jones</surname><given-names>D.</given-names></name>
<name><surname>Panchal</surname><given-names>A.R.</given-names></name>
</person-group><article-title>Enhanced Evasion of Neutralizing Antibody Response by Omicron XBB. 1.5, CH. 1.1, and CA. 3.1 Variants</article-title><source>Cell Rep.</source><year>2023</year><volume>42</volume><fpage>112443</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2023.112443</pub-id><pub-id pub-id-type="pmid">37104089</pub-id>
</element-citation></ref><ref id="B38-viruses-16-01860"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Abulsoud</surname><given-names>A.I.</given-names></name>
<name><surname>El-Husseiny</surname><given-names>H.M.</given-names></name>
<name><surname>El-Husseiny</surname><given-names>A.A.</given-names></name>
<name><surname>El-Mahdy</surname><given-names>H.A.</given-names></name>
<name><surname>Ismail</surname><given-names>A.</given-names></name>
<name><surname>Elkhawaga</surname><given-names>S.Y.</given-names></name>
<name><surname>Khidr</surname><given-names>E.G.</given-names></name>
<name><surname>Fathi</surname><given-names>D.</given-names></name>
<name><surname>Mady</surname><given-names>E.A.</given-names></name>
<name><surname>Najda</surname><given-names>A.</given-names></name>
</person-group><article-title>Mutations in SARS-CoV-2: Insights on Structure, Variants, Vaccines, and Biomedical Interventions</article-title><source>Biomed. Pharmacother.</source><year>2023</year><volume>157</volume><elocation-id>113977</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2022.113977</pub-id><pub-id pub-id-type="pmid">36370519</pub-id>
</element-citation></ref><ref id="B39-viruses-16-01860"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Planas</surname><given-names>D.</given-names></name>
<name><surname>Staropoli</surname><given-names>I.</given-names></name>
<name><surname>Michel</surname><given-names>V.</given-names></name>
<name><surname>Lemoine</surname><given-names>F.</given-names></name>
<name><surname>Donati</surname><given-names>F.</given-names></name>
<name><surname>Prot</surname><given-names>M.</given-names></name>
<name><surname>Porrot</surname><given-names>F.</given-names></name>
<name><surname>Guivel-Benhassine</surname><given-names>F.</given-names></name>
<name><surname>Jeyarajah</surname><given-names>B.</given-names></name>
<name><surname>Brisebarre</surname><given-names>A.</given-names></name>
</person-group><article-title>Distinct Evolution of SARS-CoV-2 Omicron XBB and BA. 2.86/JN. 1 Lineages Combining Increased Fitness and Antibody Evasion</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>2254</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-46490-7</pub-id><pub-id pub-id-type="pmid">38480689</pub-id>
</element-citation></ref><ref id="B40-viruses-16-01860"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vashisht</surname><given-names>V.</given-names></name>
<name><surname>Vashisht</surname><given-names>A.</given-names></name>
<name><surname>Mondal</surname><given-names>A.K.</given-names></name>
<name><surname>Farmaha</surname><given-names>J.</given-names></name>
<name><surname>Alptekin</surname><given-names>A.</given-names></name>
<name><surname>Singh</surname><given-names>H.</given-names></name>
<name><surname>Ahluwalia</surname><given-names>P.</given-names></name>
<name><surname>Srinivas</surname><given-names>A.</given-names></name>
<name><surname>Kolhe</surname><given-names>R.</given-names></name>
</person-group><article-title>Genomics for Emerging Pathogen Identification and Monitoring: Prospects and Obstacles</article-title><source>BioMedInformatics</source><year>2023</year><volume>3</volume><fpage>1145</fpage><lpage>1177</lpage><pub-id pub-id-type="doi">10.3390/biomedinformatics3040069</pub-id></element-citation></ref><ref id="B41-viruses-16-01860"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mohapatra</surname><given-names>R.K.</given-names></name>
<name><surname>Mishra</surname><given-names>S.</given-names></name>
<name><surname>Kandi</surname><given-names>V.</given-names></name>
<name><surname>Branda</surname><given-names>F.</given-names></name>
<name><surname>Ansari</surname><given-names>A.</given-names></name>
<name><surname>Rabaan</surname><given-names>A.A.</given-names></name>
<name><surname>Kudrat-E-Zahan</surname><given-names>M.</given-names></name>
</person-group><article-title>Analyzing the Emerging Patterns of SARS-CoV-2 Omicron Subvariants for the Development of Next-gen Vaccine: An Observational Study</article-title><source>Health Sci. Rep.</source><year>2023</year><volume>6</volume><fpage>e1596</fpage><pub-id pub-id-type="doi">10.1002/hsr2.1596</pub-id><pub-id pub-id-type="pmid">37867789</pub-id>
</element-citation></ref><ref id="B42-viruses-16-01860"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kyaw</surname><given-names>M.H.</given-names></name>
<name><surname>Spinardi</surname><given-names>J.R.</given-names></name>
<name><surname>Jagun</surname><given-names>O.</given-names></name>
<name><surname>Villalobos</surname><given-names>C.F.</given-names></name>
<name><surname>Kapetanakis</surname><given-names>V.</given-names></name>
<name><surname>Sharf-Williams</surname><given-names>R.</given-names></name>
<name><surname>Yarnoff</surname><given-names>B.</given-names></name>
</person-group><article-title>Descriptive Analysis to Assess Seasonal Patterns of COVID-19 and Influenza in Low-Income and Middle-Income Countries in Asia, the Middle East and Latin America</article-title><source>BMJ Open</source><year>2024</year><volume>14</volume><fpage>e081019</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2023-081019</pub-id><pub-id pub-id-type="pmid">38296298</pub-id>
</element-citation></ref><ref id="B43-viruses-16-01860"><label>43.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention (CDC)</collab>
</person-group><article-title>COVID Data Tracker</article-title><comment>Available online: <ext-link xlink:href="https://covid.cdc.gov/covid-data-tracker/#datatracker-home" ext-link-type="uri">https://covid.cdc.gov/covid-data-tracker/#datatracker-home</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-15">(accessed on 15 May 2024)</date-in-citation></element-citation></ref><ref id="B44-viruses-16-01860"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Quarleri</surname><given-names>J.</given-names></name>
<name><surname>Delpino</surname><given-names>M.V.</given-names></name>
<name><surname>Galvan</surname><given-names>V.</given-names></name>
</person-group><article-title>Anticipating the Future of the COVID-19 Pandemic: Insights into the Emergence of SARS-CoV-2 Variant JN.1 and Its Projected Impact on Older Adults</article-title><source>GeroScience</source><year>2024</year><volume>46</volume><fpage>2879</fpage><lpage>2883</lpage><pub-id pub-id-type="doi">10.1007/s11357-024-01066-7</pub-id><pub-id pub-id-type="pmid">38198026</pub-id>
</element-citation></ref><ref id="B45-viruses-16-01860"><label>45.</label><element-citation publication-type="webpage"><article-title>GISAID</article-title><comment>Available online: <ext-link xlink:href="https://gisaid.org/hcov19-variants/" ext-link-type="uri">https://gisaid.org/hcov19-variants/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-15">(accessed on 15 May 2024)</date-in-citation></element-citation></ref><ref id="B46-viruses-16-01860"><label>46.</label><element-citation publication-type="webpage"><person-group person-group-type="author">
<collab>World Health Organization (WHO)</collab>
</person-group><article-title>COVID-19 Dashboard</article-title><comment>Available online: <ext-link xlink:href="https://data.who.int/dashboards/covid19/variants/" ext-link-type="uri">https://data.who.int/dashboards/covid19/variants/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-05-15">(accessed on 15 May 2024)</date-in-citation></element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-16-01860-f001"><label>Figure 1</label><caption><p>Distribution of SARS-CoV-2 lineages over time (April 2023 to March 2024).</p></caption><graphic xlink:href="viruses-16-01860-g001" position="float"/></fig><fig position="float" id="viruses-16-01860-f002"><label>Figure 2</label><caption><p>Number of SARS-CoV-2 lineages according to vaccination status. The XBB.1 SARS-CoV-2 lineage generally dominated in both vaccinated and non-vaccinated individuals as well as those whose vaccination status was unknown.</p></caption><graphic xlink:href="viruses-16-01860-g002" position="float"/></fig><fig position="float" id="viruses-16-01860-f003"><label>Figure 3</label><caption><p>Mutation profile analysis according to SARS-CoV-2 lineages. Plots show the number of nucleotide mutations (panel (<bold>a</bold>)), associated amino acid mutations (panel (<bold>b</bold>)) and spike amino acid mutations (panel (<bold>c</bold>)).</p></caption><graphic xlink:href="viruses-16-01860-g003" position="float"/></fig><fig position="float" id="viruses-16-01860-f004"><label>Figure 4</label><caption><p>Maximum likelihood phylogenetic tree (1000 bootstraps). Includes 163 SARS-CoV-2 sequences from the COVVAR study and 206 Ugandan sequences from the GISAID database.</p></caption><graphic xlink:href="viruses-16-01860-g004" position="float"/></fig><table-wrap position="float" id="viruses-16-01860-t001"><object-id pub-id-type="pii">viruses-16-01860-t001_Table 1</object-id><label>Table 1</label><caption><p>Number and Proportion of SARS-CoV-2 Lineage assignment and vaccine status.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Lineage</th><th rowspan="2" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Sub Lineages (<italic toggle="yes">n</italic>)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">All<break/>(<italic toggle="yes">n</italic> = 163)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccinated <break/>(<italic toggle="yes">n</italic> = 107) </th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Unvaccinated <break/>(<italic toggle="yes">n</italic> = 53)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Unknown Vaccination Status (<italic toggle="yes">n</italic> = 3)</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%) </th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">n</italic> (%)</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CM</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CM.8.1 (4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (2.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (1.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (3.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EG</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EG.2 (1), EG.5.2 (6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (4.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (4.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (3.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FL</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FL.1.5.1(1), FL.10(4), FL.10.2 (1), FL.13.4.1 (1), FL.2.2 (4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (6.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (6.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (7.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">JN.1 </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">JN.1 (10), JN.1.18 (1), JN.1.4.7 (1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (7.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (7.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4(7.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Others </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BQ.1.1 (1), FY.4.1 (1), FY.4.1.2 (1), GY.2.1 (1), HK.27.1 (1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (3.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (3.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.1</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.1 (2), XBB.1.16 (21), XBB.1.16.1 (6), XBB.1.34.1 (14), XBB.1.5 (54), XBB.1.5.12 (2), XBB.1.5.28 (2), XBB.1.5.63 (2), XBB.1.9.1 (10)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">113 (69.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73 (68.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37 (69.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (100)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.2</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XBB.2.3 (6), XBB.2.3.11 (2), XBB.2.3.4 (3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (6.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (7.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (5.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr></tbody></table><table-wrap-foot><fn><p><italic toggle="yes">n</italic>, number; %, column percentage.</p></fn></table-wrap-foot></table-wrap></floats-group></article>